ET-01 in Subjects With Lateral Canthal Lines

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-25

Study Completion Date

2018-11-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ET-01 in Subjects With Lateral Canthal Lines, LCL-209

NCT03912805

Lateral Canthal Lines, LCL Crow's Feet

COMPLETED PHASE2

ET-01 in Subjects With Lateral Canthal Lines, LCL-208

NCT03839693

Lateral Canthal Lines Crow's Feet

COMPLETED PHASE2

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

NCT04985916

Lateral Canthal Lines, LCL Crow's Feet

COMPLETED PHASE2

Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)

NCT00247559

Lateral Canthal Lines

COMPLETED PHASE2

BOTOX® in the Treatment of Crow's Feet Lines in Japan

NCT01797081

Lateral Canthus Rhytides Crow's Feet Lines

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This product is being tested for its ability to reduce lateral canthal lines, also known as Crow's Feet.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lateral Canthal Lines Crow's Feet

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

sequential, dose escalating study

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vehicle

Group Type PLACEBO_COMPARATOR

Vehicle

Intervention Type BIOLOGICAL

Vehicle Formulation

Dose 1

botulinum toxin, Type A, Dose 1

Group Type EXPERIMENTAL

botulinum toxin, Type A

Intervention Type BIOLOGICAL

topical liniment

Dose 2

botulinum toxin, Type A, Dose 2

Group Type EXPERIMENTAL

botulinum toxin, Type A

Intervention Type BIOLOGICAL

topical liniment

Dose 3

botulinum toxin, Type A, Dose 3

Group Type EXPERIMENTAL

botulinum toxin, Type A

Intervention Type BIOLOGICAL

topical liniment

Dose 4

botulinum toxin, Type A, Dose 4

Group Type EXPERIMENTAL

botulinum toxin, Type A

Intervention Type BIOLOGICAL

topical liniment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

botulinum toxin, Type A

topical liniment

Intervention Type BIOLOGICAL

Vehicle

Vehicle Formulation

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ET-01

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 25 - 65 years of age
* minimal to moderate Crow's Feet wrinkles at rest
* moderate to severe Crow's Feet wrinkles on contraction
* willingness to refrain from any product affecting skin remodeling
* female subjects must be not pregnant and non-lactating-

Exclusion Criteria

* history of adverse reactions to any prior botulinum toxin treatments
* history of vaccination or non-response to any prior botulinum toxin treatments
* botulinum toxin treatment in the prior 6 months
* present or history of neuromuscular disease, eyelid ptosis, muscle weakness, paralysis, or "dry eye"
* history of peri-ocular surgery, brow lift or related procedures
* procedures affecting the lateral canthal region in the prior 12 months
* application of topical prescription medication to the treatment area
* female subjects who are pregnant or are nursing a child

Minimum Eligible Age

25 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No